ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock? [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
private biotech Nimble Therapeutics, which will add the latter's lead pipeline candidate, an oral peptide IL23R inhibitor in preclinical development for psoriasis. The acquisition will strengthen AbbVie's immunology pipeline. Nimble is also making oral peptide-based therapeutics for autoimmune diseases leveraging its proprietary peptide synthesis platform. To acquire Nimble, AbbVie will make a cash payment of $200 million. Nimble will also be entitled to some potential milestone payments. AbbVie on an Acquisition Spree This Year AbbVie has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. It has signed several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. In 2024, it acquired smaller biotechs like Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating inflammatory bowel disease (IBD), which has become quite a popular space
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Chemotherapy Treatment Market Research Report 2024-2030: Advancements in Targeted Chemotherapy and Personalized Treatment Plan Developments Driving Growth [Yahoo! Finance]Yahoo! Finance
- Glaucoma Surgical Devices Market to Hit Valuation of US$ 1,546 Million by 2033 | Astute Analytica [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs [Yahoo! Finance]Yahoo! Finance
- Is AbbVie Stock a Buy? [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/30/24 - Beat
ABBV
Sec Filings
- 12/18/24 - Form 4
- 12/16/24 - Form 144
- 12/13/24 - Form 8-K
- ABBV's page on the SEC website